Capstone Therapeutics Corporation has announced a significant cost rationalization program, eliminating approximately $2.0 million in annualized corporate overhead expenses effective immediately. The company expects these measures to materially improve its financial performance, with management targeting a positive EBITDA run-rate beginning in the second quarter of 2026, independent of revenue growth. The impact of these cost reductions will begin to be reflected in the first quarter and become clear by the quarter ending June 30, 2026. The CEO has also reduced his annual cash salary to $1.00 to align executive compensation with shareholder equity appreciation. Capstone plans to release an earnings power presentation in early February outlining a range of EBITDA expectations under various macroeconomic assumptions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1129547) on January 21, 2026, and is solely responsible for the information contained therein.